Docality.com Logo
 
Dr. Zahid  Zafar  Md image

Dr. Zahid Zafar Md

5309 W University Dr
Mckinney TX 75071
972 621-1018
Medical School: Other - 1992
Accepts Medicare: Yes
Participates In eRX: Yes
Participates In PQRS: No
Participates In EHR: Yes
License #: K9943
NPI: 1043209075
Taxonomy Codes:
207R00000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Zahid Zafar is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:99291 Description:Critical care first hour Average Price:$491.00 Average Price Allowed
By Medicare:
$208.31
HCPCS Code:77080 Description:Dxa bone density axial Average Price:$250.00 Average Price Allowed
By Medicare:
$54.98
HCPCS Code:99235 Description:Observ/hosp same date Average Price:$349.00 Average Price Allowed
By Medicare:
$157.72
HCPCS Code:93923 Description:Upr/lxtr art stdy 3+ lvls Average Price:$323.00 Average Price Allowed
By Medicare:
$146.83
HCPCS Code:99223 Description:Initial hospital care Average Price:$306.43 Average Price Allowed
By Medicare:
$182.00
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$262.00 Average Price Allowed
By Medicare:
$151.54
HCPCS Code:99222 Description:Initial hospital care Average Price:$220.00 Average Price Allowed
By Medicare:
$127.14
HCPCS Code:99239 Description:Hospital discharge day Average Price:$187.00 Average Price Allowed
By Medicare:
$98.71
HCPCS Code:G0180 Description:MD certification HHA patient Average Price:$137.00 Average Price Allowed
By Medicare:
$49.57
HCPCS Code:99309 Description:Nursing fac care subseq Average Price:$168.52 Average Price Allowed
By Medicare:
$84.47
HCPCS Code:99238 Description:Hospital discharge day Average Price:$138.00 Average Price Allowed
By Medicare:
$66.57
HCPCS Code:G0179 Description:MD recertification HHA PT Average Price:$104.00 Average Price Allowed
By Medicare:
$38.19
HCPCS Code:99233 Description:Subsequent hospital care Average Price:$154.21 Average Price Allowed
By Medicare:
$95.92
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$156.00 Average Price Allowed
By Medicare:
$98.17
HCPCS Code:93000 Description:Electrocardiogram complete Average Price:$70.00 Average Price Allowed
By Medicare:
$17.65
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$109.00 Average Price Allowed
By Medicare:
$66.86
HCPCS Code:G0438 Description:PPPS, initial visit Average Price:$197.50 Average Price Allowed
By Medicare:
$157.03
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$105.00 Average Price Allowed
By Medicare:
$66.27
HCPCS Code:83037 Description:Glycosylated hb home device Average Price:$50.00 Average Price Allowed
By Medicare:
$13.75
HCPCS Code:99211 Description:Office/outpatient visit est Average Price:$40.00 Average Price Allowed
By Medicare:
$18.32
HCPCS Code:85610 Description:Prothrombin time Average Price:$20.00 Average Price Allowed
By Medicare:
$5.56
HCPCS Code:96372 Description:Ther/proph/diag inj sc/im Average Price:$35.00 Average Price Allowed
By Medicare:
$22.33
HCPCS Code:81003 Description:Urinalysis auto w/o scope Average Price:$15.00 Average Price Allowed
By Medicare:
$3.18
HCPCS Code:81002 Description:Urinalysis nonauto w/o scope Average Price:$14.91 Average Price Allowed
By Medicare:
$3.62
HCPCS Code:Q2037 Description:Fluvirin vacc, 3 yrs & >, im Average Price:$25.00 Average Price Allowed
By Medicare:
$14.05
HCPCS Code:J3301 Description:Triamcinolone acet inj NOS Average Price:$5.00 Average Price Allowed
By Medicare:
$1.69
HCPCS Code:G0008 Description:Admin influenza virus vac Average Price:$25.00 Average Price Allowed
By Medicare:
$22.51

HCPCS Code Definitions

77080
Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)
93000
Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report
93923
Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure measurements with bidirectional Doppler waveform recording and analysis, at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental volume plethysmography at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental transcutaneous oxygen tension measurements at 3 or more levels), or single level study with provocative functional maneuvers (eg, measurements with postural provocative tests, or measurements with reactive hyperemia)
96372
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
99211
Office or other outpatient visit for the evaluation and management of an established patient, that may not require the presence of a physician or other qualified health care professional. Usually, the presenting problem(s) are minimal. Typically, 5 minutes are spent performing or supervising these services.
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99222
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of moderate severity. Typically, 50 minutes are spent at the bedside and on the patient's hospital floor or unit.
99223
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of high severity. Typically, 70 minutes are spent at the bedside and on the patient's hospital floor or unit.
99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.
99233
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.
99235
Observation or inpatient hospital care, for the evaluation and management of a patient including admission and discharge on the same date, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually the presenting problem(s) requiring admission are of moderate severity. Typically, 50 minutes are spent at the bedside and on the patient's hospital floor or unit.
99238
Hospital discharge day management; 30 minutes or less
99239
Hospital discharge day management; more than 30 minutes
99291
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes
99309
Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient has developed a significant complication or a significant new problem. Typically, 25 minutes are spent at the bedside and on the patient's facility floor or unit.
G0008
Administration of influenza virus vaccine
G0179
Physician re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial implementation of the plan of care that meets patient's needs, per re-certification period
G0180
Physician certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial implementation of the plan of care that meets patient's needs, per certification period
G0438
Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit
J3301
Injection, triamcinolone acetonide, not otherwise specified, 10 mg
Q2037
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1386634293
Internal Medicine
14,018
1225023948
Hematology/Oncology
5,329
1851359525
Diagnostic Radiology
4,616
1528061108
Internal Medicine
4,354
1952359119
Diagnostic Radiology
4,109
1063407740
Internal Medicine
3,941
1083691919
Pulmonary Disease
3,341
1316937394
Cardiovascular Disease (Cardiology)
2,994
1417927393
Cardiovascular Disease (Cardiology)
2,713
1588678437
Internal Medicine
2,439
*These referrals represent the top 10 that Dr. Zafar has made to other doctors

Publications

Recovery of Schistosoma haematobium ovum from Labeo rohita: first report from Pakistan. - Tropical biomedicine
Schistosomiasis, also known as bilharzia, is a parasitic disease caused by trematodes from the genus Schistosoma that can infect humans and animals. S. mansoni, S. japonicum, and S. mekongi all causes intestinal schistosomiasis except S. haematobium that causes urinary schistosomiasis. It is only specie which effects urinary system, it can affect liver, heart, lungs also but very rarely. Schistosoma haematobium is endemic to over 50 countries in Africa and the Middle East and Western Asia and may be fatal in HIV positive people. A number of reports from the African countries like Nigeria have been reported. A few cases are reported but in Pakistan it has never been reported before in native people. It is first time reported in Pakistan in the intestine of Rahu (Labeo rohita). The purpose of this study is to elaborate the approach of zoonotic agent by various other routes including the commonly available fish.
Mammary myofibroblastoma: a clinico- pathologic study of six cases. - Breast disease
Mammary myofibroblastoma is a rare and benign neoplasm of the breast stroma, showing features of fibroblasts and myofibroblasts. It has also been noted to exhibit smooth muscle cell characteristics.The aim of this study was to describe the clinical and pathological features of mammary myofibroblastoma reported at our institution.Cases of mammary myofibroblastoma reported in our laboratory were retrieved by electronic search. H&E slides were reviewed and clinico-pathologic features were noted. Immunohistochemistery was performed by Envision method. Only CD34 and CKAE1/AE3 were performed in all 6 cases. ASMA, desmin and S-100 were performed in 5, 4 and 2 cases, respectively. Vimentin and Bcl-2 were performed in one case.A total of 6 cases were identified. Five were female and one was male. The mean age of patients was 45.5 years. The mean size of tumors was 7.7 cm in the largest dimension. Histologically, four cases showed clusters of uniform bipolar spindle shaped cells separated by broad bands of hyalinized collagen. Mitotic figures ranged from none to 3 mitoses/10 HPFs. One case showed combined features of cellular and fibrous areas. Another case was epithelioid-cell type. On immunohistochemistry, CD34 stain was positive in 5/6 cases, ASMA in 3/5 cases, desmin in 2/4 cases, S-100 in none and vimentin and Bcl-2 in 1/6 cases. None of the cases stained positive for CKAE1/AE3.Due to the varying degree of fibro-myofibroblastic differentiation, myofibroblastoma shows multiple morphologies and several intratumoral and intertumoral types. It is essential to distinguish each variant from the other to avoid inaccurate diagnosis of other benign or malignant breast conditions, becoming a noteworthy diagnostic dilemma for histopathologists.
Molecular characterization and identification of plant growth promoting endophytic bacteria isolated from the root nodules of pea (Pisum sativum L.). - World journal of microbiology & biotechnology
Root nodule accommodates various non-nodulating bacteria at varying densities. Present study was planned to identify and characterize the non-nodulating bacteria from the pea plant. Ten fast growing bacteria were isolated from the root nodules of cultivated pea plants. These bacterial isolates were unable to nodulate pea plants in nodulation assay, which indicate the non-rhizobial nature of these bacteria. Bacterial isolates were tested in vitro for plant growth promoting properties including indole acetic acid (IAA) production, nitrogen fixation, phosphate solubilization, root colonization and biofilm formation. Six isolates were able to produce IAA at varying level from 0.86 to 16.16 μg ml(-1), with the isolate MSP9 being most efficient. Only two isolates, MSP2 and MSP10, were able to fix nitrogen. All isolates were able to solubilize inorganic phosphorus ranging from 5.57 to 11.73 μg ml(-1), except MSP4. Bacterial isolates showed considerably better potential for colonization on pea roots. Isolates MSP9 and MSP10 were most efficient in biofilm formation on polyvinyl chloride, which indicated their potential to withstand various biotic and abiotic stresses, whereas the remaining isolates showed a very poor biofilm formation ability. The most efficient plant growth promoting agents, MSP9 and MSP10, were phylogenetically identified by 16S rRNA gene sequence analysis as Ochrobactrum and Enterobacter, respectively, with 99% similarity. It is suggested the potential endophytic bacterial strains, Ochrobactrum sp. MSP9 and Enterobacter sp. MSP10, can be used as biofertilizers for various legume and non-legume crops after studying their interaction with the host crop and field evaluation.
Huge sub-mandibular gland tumour. - Journal of Ayub Medical College, Abbottabad : JAMC
Salivary gland neoplasms are a diverse group of tumours and appropriate treatment depends on adequate understanding of the pathophysiologic behaviour of each tumour type. Most (95%) salivary glands occur in adults. Benign tumours are slow growing tumours and attain a considerable size before presenting to surgeon. We report a case of huge tumour of left submandibular gland that presented in our surgical outpatient department, and had developed over last twenty years. It was diagnosed as a benign mixed tumour of salivary gland and was successfully excised. Histopathology confirmed it to be a benign pleomorphic adenoma.
Novel cycloartane saponins from Corchorus depressus L. - Chemical & pharmaceutical bulletin
Two novel bidesmosidic cycloartane-type glycosides, depressosides C and D were isolated from Corchorus depressus L. Their structures were elucidated as (22R)-16beta,22-epoxy-3beta,26-dihydroxy-9,19-cyclolanost-++ +24E-ene 3, 26-di-O-beta-D-glucopyranoside and (22R,24S)-22,25-epoxy-3beta,16beta,24-trihydroxy-9,19-cyclolano stane 3, 24-di-O-beta-glucopyranoside, respectively on the basis of chemical evidence and detailed spectroscopic studies.

Map & Directions

5309 W University Dr Mckinney, TX 75071
View Directions In Google Maps

Nearby Doctors

1790 N Stonebridge Dr
Mckinney, TX 75071
972 909-9002
5252 W University Dr
Mckinney, TX 75071
469 646-6950
2709 Virginia Pkwy Ste 200
Mckinney, TX 75071
972 482-2015
2740 Virginia Pkwy Suite 100
Mckinney, TX 75071
972 422-2277
5252 W University Dr Attn: Mkipcu
Mckinney, TX 75071
469 646-6950
5881 Virginia Pkwy Ste 300
Mckinney, TX 75071
972 690-0214
5236 W University Dr Suite 2200
Mckinney, TX 75071
469 005-5036
5236 W University Dr #3300
Mckinney, TX 75071
972 624-4430
6587 Virginia Parkway
Mckinney, TX 75071
972 488-8382
1872 N. Lake Forest Dr.
Mckinney, TX 75071
972 480-0758